Articles tagged "Pancreas transplantation"

2021 American Transplant Congress
Islet Isograft Transplantation Improves Insulin Sensitivity in a Murine Model of Type 2 Diabetes
S. Lim, M. Choi, M. Kim, Y. Wee, H. Kwon, C. Jung, Y. Kim, D. Han, S. Shin
Asan Medical Center, Seoul, Songpa, Korea, Republic of
*Purpose: Type 2 diabetes develops in the presence of chronic overnutrition and genetic susceptibility, and causes insulin resistance and relative insulin deficiency. We hypothesized that…
2021 American Transplant Congress
Donor Derived Cell Free DNA Identifies Rejection in Simultaneous Pancreas Kidney Transplant Recipients
M. Williams¹, S. Ghosh², L. L. Jenkins², M. Hertl¹, S. Saltzberg³, V. Peev³, E. Chan¹, E. Hollinger¹, E. Schadde¹, O. Olaitan¹
¹Department of Surgery, Rush University Medical Center, Chicago, IL, ²CareDx, Inc., Brisbane, CA, ³Department of Internal Medicine, Rush University Medical Center, Chicago, IL
*Purpose: Increased level of donor-derived cell-free DNA (dd-cfDNA) has proven to be a sensitive marker for allograft rejection after solid organ transplant, particularly heart and…
2021 American Transplant Congress
Bone Marrow-Derived Mesenchymal Stem Cells Improve Rat Islet Graft Revascularization by Upregulating Isl1
W. Ying, J. Wang, X. Ding
Kidney Transplantation, The First Affiliated Hospital of Xi'an Jiaotong University, Xi An, China
*Purpose: Revascularization of the transplant islet is a crucial step that defines the success rate of patient recovery. Though bone marrow-derived mesenchymal stem cells (BMSCs)…
2021 American Transplant Congress
Controlled Donation After Circulatory Death Pancreas Transplantation in Spain. Initial Experience
J. Ferrer-Fàbrega¹, R. Muñoz², J. Ruiz³, D. Casanova⁴, F. Sánchez-Bueno⁵, J. Pérez-Daga⁶, C. Fernández-Rivera⁷, M. Gómez⁸, F. Castillo⁹, R. López-Andújar¹⁰, J. Maupoey¹⁰, J. Briceño¹¹, J. Sánchez-Hidalgo¹¹, Á. Arjona¹¹, A. Álvarez¹², A. Alarcó¹³, A. Bravo¹³, R. García¹, R. Rull¹, M. López-Boado¹, P. Ventura-Aguiar¹⁴, F. Diekmann¹⁴, D. Paredes¹⁵, J. García-Valdecasas¹, J. Fuster¹, C. Fondevila¹, B. Domínguez-Gil²
¹Hepatobiliopancreatic Surgery and Transplantation Department, Hospital Clínic Barcelona, Barcelona, Spain, ²Organización Nacional de Trasplantes (ONT), Madrid, Spain, ³Department of Nephrology., University Hospital Marques de Valdecilla. University Cantabria, Santander., Santander, Spain, ⁴Department of Surgery, University Hospital Marques de Valdecilla, University Cantabria, Santander., Santander, Spain, ⁵Department of General, Visceral and Transplantation Surgery., Clinic and University Hospital Virgen de la Arrixaca. IMIB-ARRIXACA. Murcia., Murcia, Spain, ⁶Department of Surgery, Hospital Regional de Málaga. Málaga., Málaga, Spain, ⁷Department of Nephrology., Complexo Hospitalario Universitario de A Coruña. A Coruña, A Coruña, Spain, ⁸Department of Surgery, Complexo Hospitalario Universitario de A Coruña. A Coruña, A Coruña, Spain, ⁹Department of Surgery, University Hospital Marques de Valdecilla. University Cantabria, Santander., Santander, Spain, ¹⁰Hepato-Pancreatico-Biliary Surgery and Transplant Unit, La Fe University Hospital. Valencia, Valencia, Spain, ¹¹Department of Surgery, Hospital Universitario Reina Sofía. Córdoba, Córdoba, Spain, ¹²Department of Nephrology., Hospital Universitario de Canarias. Tenerife., Tenerife, Spain, ¹³Department of Surgery, Hospital Universitario de Canarias. Tenerife., Tenerife, Spain, ¹⁴Renal Transplant Unit, Hospital Clínic Barcelona, Barcelona, Spain, ¹⁵Coordination Department, Hospital Clínic Barcelona, Barcelona, Spain
*Purpose: To report on the Spanish Pancreas Transplantation experience in controlled donation after circulatory death (cDCD) by analyzing the normothermic regional perfusion (NRP) and super-rapid…
2021 American Transplant Congress
Induction in Pancreas Transplantation: T-Cell Depletion vs. Il-2 Receptor Blockade
F. Aziz, S. Parajuli, D. Kaufman, J. Odorico, D. Mandelbrot
University of Wisconsin, Madison, WI
*Purpose: There are limited data comparing outcomes with different induction agents in pancreas transplantation. In this study, we compare T-cell depletion to IL-2 receptor (IL2R)…
2021 American Transplant Congress
Update on Pancreas Retransplantation- A Registry Analysis
A. Gruessner, J. Renz, S. Saggi, R. Gruessner
SUNY Downstate Medical Center, Brooklyn, NY
*Purpose: A successful pancreas transplant provides patients with brittle diabetes the opportunity of good long-term metabolic control. While initially more and more retransplants were performed,…
2021 American Transplant Congress
Development of De-novo Malignancies After Kidney and/or Pancreas Transplantation in Diabetic Patients
A. Gruessner, S. Saggi, J. Renz, R. Gruessner
SUNY Downstate Medical Center, Brooklyn, NY
*Purpose: Transplantation of a kidney (KTA), pancreas (PTA), or a simultaneous pancreas-kidney (SPK) in a patient with end-stage organ failure is a lifesaving treatment. Patient…
2021 American Transplant Congress
Symptoms on MTSOSD Questionnaire in Pancreas Transplantation Recipients
R. Kaur, S. R. Rizvi, B. H. Smith, C. Reid, S. K. McCrady-Spitzer, W. K. Kremers, P. G. Dean, A. Kukla, M. D. Stegall, Y. C. Kudva
Mayo Clinic, Rochester, MN
*Purpose: We used the Modified transplant symptom Occurrence and symptom distress scale (MTSOSD) to study side-effects of immunosuppression after Pancreas transplantation (PT) for patients with…
2021 American Transplant Congress
Dual-Agent Induction Therapy for Pancreas Transplantation: A Single-center Experience
E. C. Liu¹, J. H. Lee¹, R. Craig-Schapiro², M. Aull², S. Sultan²
¹Pharmacy, NewYork-Presbyterian Weill Cornell Medical Center, New York, NY, ²Kidney/Pancreas Transplant Surgery, NewYork-Presbyterian Weill Cornell Medical Center, New York, NY
*Purpose: The optimal induction strategy in pancreas transplantation has not been elucidated. Available evidence supports use of both basiliximab and lymphocyte depleting agents. Rabbit anti-thymocyte…
2021 American Transplant Congress
Impact of Insulin Therapy in Pancreas Transplantation Donors on Graft Outcomes: An Analysis of the Optn/unos Database
E. Montagud-Marrahi¹, F. Ausania², Y. Fundora², A. Amor³, E. Esmatjes³, J. Ferrer², I. Revuelta¹, D. Cucchiari¹, J. Rovira⁴, M. Musquera⁵, C. Fondevila², F. Diekmann¹, P. Ventura-Aguiar¹
¹Nephrology and Kidney Transplantation Department, Hospital Clinic de Barcelona, Barcelona, Spain, ²Hepatobiliopancreatic and Liver Transplant Department, Hospital Clinic de Barcelona, Barcelona, Spain, ³Endocrinology Department, Hospital Clinic de Barcelona, Barcelona, Spain, ⁴Laboratori Experimental de Nefrologia I Trasplantament (LENIT), CRB CELLEX, Fundació Clínic, IDIBAPS, Hospital Clinic de Barcelona, Barcelona, Spain, ⁵Urology Department, Hospital Clinic de Barcelona, Barcelona, Spain
*Purpose: Hyperglycemia requiring insulin treatment is frequent in critically ill patients and potential pancreas donors. Information on the impact of donor insulin use on pancreas…